argenx SE (ARGX)
Nasdaq (ADR) / Euronext Brussels · Amsterdam, Netherlands · Founded 2008 · CEO Karen Massey
Valuation summary
$725.86 fair value versus $942.04 in the market, a difference of -22.9%. Rated Reduce.
| Fair value per share | $725.86 |
| Current share price | $942.04 |
| Upside / downside | -22.9% |
| Bear case | $486.17 |
| Bull case | $1,059.70 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 3.00% |
| Market capitalisation | $59B |
| EV / Sales | 11.1x |
About argenx SE
Founded in 2008 by Tim Van Hauwermeiren, Hans de Haard and Torsten Dreier, growing out of antibody research in Belgium. Karen Massey, previously chief operating officer, is chief executive. argenx makes Vyvgart, a treatment for autoimmune diseases such as myasthenia gravis and the nerve disorder CIDP that works by clearing the harmful antibodies from the blood. Vyvgart has become one of the most successful drug launches in immunology, and the company is testing it and newer medicines in many more diseases.
Investment case
- Vyvgart is still gaining patients in its approved uses and adding new ones.
- A convenient pre-filled syringe lets patients treat themselves at home.
- Profitable, with a large cash balance to fund a broad pipeline.
Key risks
- Almost all revenue comes from one medicine.
- Competing antibody-clearing drugs from Johnson & Johnson, UCB and others.
- Clinical trials in new diseases can fail.
Revenue by segment
| Vyvgart franchise | 98% |
| Collaborations and other | 2% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $7.6B | $1.9B |
| Year 2 | $9.5B | $2.3B |
| Year 3 | $11.2B | $2.6B |
| Year 4 | $12.8B | $2.9B |
| Year 5 | $14.2B | $3.1B |
What the street says
One of Europe's most admired biotech companies; expectations for label expansion are high.
Comparable companies: EW · REGN · IDXX · A · ISRG · SNY · VRTX · RMD
Open the interactive model, price chart and sensitivity grid →